var data={"title":"Rifaximin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rifaximin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6915?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rifaximin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rifaximin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=rifaximin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rifaximin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218514\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Xifaxan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48898244\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zaxine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218531\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218516\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic encephalopathy:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reduction of overt hepatic encephalopathy recurrence: 550 mg 2 times daily. <b>Note:</b> Supporting clinical trial evaluated efficacy over 6-month treatment period.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of hepatic encephalopathy (off-label use): 400 mg every 8 hours for 5 to 10 days (Mas 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Irritable bowel syndrome with diarrhea (IBS-D):</b> Oral: 550 mg 3 times daily for 14 days; may be retreated up to 2 times with the same dosing regimen if symptoms recur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler's diarrhea:</b> Oral: 200 mg 3 times daily for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Clostridium difficile</i></b>\n      <b>-associated diarrhea (off-label use):</b> Oral: 200 to 400 mg 2 to 3 times daily for 14 days (Johnson 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218524\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=rifaximin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rifaximin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Traveler's diarrhea:</b> Oral: Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218517\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10167004\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10167005\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. Use with caution in severe impairment (Child-Pugh class C); however, systemic absorption is limited and pharmacokinetic parameters are highly variable.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218495\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xifaxan: 200 mg [contains edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xifaxan: 550 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218483\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48902902\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zaxine: 550 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218498\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218497\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic encephalopathy:</b> Reduction in the risk of overt hepatic encephalopathy recurrence in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Irritable bowel syndrome with diarrhea:</b> Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Traveler's diarrhea:</b> Treatment of traveler's diarrhea caused by noninvasive strains of <i>E. coli</i> in adults and pediatric patients &ge;12 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Rifaximin should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea caused by pathogens other than <i>E. coli</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725118\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Clostridium difficile infection (recurrent); Overt hepatic encephalopathy episodes (treatment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F803022\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">RifAXIMin may be confused with rifAMPin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218487\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency of adverse events generally higher following treatment for hepatic encephalopathy (HE). Percentages are presented for HE unless otherwise stated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Peripheral edema (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (13%), fatigue (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Ascites (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (14%; irritable bowel syndrome with diarrhea 2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">2% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (travelers' diarrhea 10%), depression (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatological: Pruritus (9%), skin rash (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain (&gt;2% to 9%), pseudomembranous colitis (&lt;5%; travelers' diarrhea or irritable bowel syndrome with diarrhea &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum ALT (irritable bowel syndrome with diarrhea 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Muscle spasm (9%), arthralgia (6%), increased creatine phosphokinase (&lt;5%; travelers' diarrhea or irritable bowel syndrome with diarrhea &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Nasopharyngitis (7%), dyspnea (6%), epistaxis (&gt;2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>All indications:</b> &lt;2%, postmarketing, and/or case reports: Anaphylaxis, angioedema, <i>Clostridium difficile</i> associated diarrhea, exfoliative dermatitis, flushing, hypersensitivity reaction, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218501\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to rifaximin, other rifamycin antibiotics, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218485\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Hypersensitivity reactions (eg, exfoliative dermatitis, rash, urticaria, flushing, angioneurotic edema, pruritus, anaphylaxis) have occurred; these events have occurred as early as within 15 minutes of drug administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diarrhea: Appropriate use: Avoid use in diarrhea with fever and/or blood in the stool and in the treatment of diarrhea due to pathogens other than <i>E. coli</i>, including <i>C. jejuni</i>, <i>Shigella</i>, and <i>Salmonella</i> (efficacy has not been established). Consider alternative therapy if symptoms persist or worsen after 24 to 48 hours of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Efficacy for prevention of encephalopathy has not been established in patients with a Model for End-Stage Liver Disease (MELD) score &gt;25; use caution in patients with severe hepatic impairment (Child-Pugh class C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Not for treatment of systemic infections; &lt;1% is absorbed orally.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218525\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), OATP1A2/SLCO1A2, OATP1B1/SLCO1B1, OATP1B3/SLCO1B3, P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> OATP1A2/SLCO1A2, OATP1B1/SLCO1B1, OATP1B3/SLCO1B3</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218489\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10202&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of RifAXIMin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of RifAXIMin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218503\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Due to the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the fetus is expected to be low. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218504\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if rifaximin is excreted in human milk. According to the manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Because of the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the nursing infant is expected to be low. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218493\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity reactions, temperature, blood in stool, change in symptoms; monitor changes in mental status in hepatic encephalopathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218484\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Rifaximin inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218500\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Traveler's diarrhea: Low</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic encephalopathy: Increased absorption in patients with Child-Pugh class C compared with patients with Child-Pugh class A</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Healthy subjects: 67.5%; Hepatic impairment: 62%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensive, mainly by CYP3A</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Healthy subjects: 5.6 hours; IBS-D patients: 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Healthy subjects and ISB-D patients: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (96.6%; primarily as unchanged drug); urine (0.32%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218502\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Xifaxan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $667.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">550 mg (60): $2,545.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539924\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aximin (BD);</li>\n      <li>Bang Yi (CN);</li>\n      <li>Colidimin (AT);</li>\n      <li>Coloximina (AR);</li>\n      <li>Faxinorm (DK);</li>\n      <li>Flonorm (CO, CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Henlix (BD);</li>\n      <li>Ifaxim (CO);</li>\n      <li>Lormyx (GR, IL);</li>\n      <li>Normiks (UA);</li>\n      <li>Normix (AR, BG, CL, CZ, HN, IT, KR, LB, PH, SK, TR, VN);</li>\n      <li>Qian Er Fen (CN);</li>\n      <li>Refero (HK, PT);</li>\n      <li>Rifadom (AR);</li>\n      <li>Rifatime (IN);</li>\n      <li>Rifax (BD);</li>\n      <li>Rifaxin (BD);</li>\n      <li>Rifxima (JP);</li>\n      <li>Spiraxin (ES);</li>\n      <li>Targaxan (GB, IE);</li>\n      <li>Tixtar (ES);</li>\n      <li>Tixteller (NL);</li>\n      <li>Tixtetller (ES);</li>\n      <li>Xifamin (BD);</li>\n      <li>Xifaxan (AU, BB, DE, HK, NL, NO, NZ, PL, SG);</li>\n      <li>Xifaxanta (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bass NM, Mullen KD, Sanyal A, et al, &ldquo;Rifaximin Treatment in Hepatic Encephalopathy,&rdquo; <i>N Engl J Med</i>, 2010, 362(12):1071-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/20335583/pubmed\" target=\"_blank\" id=\"20335583\">20335583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ford AC, Moayyedi P, Lacy BE, et al. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. <i>Am J Gastroenterol</i>. 2014;109 (suppl 1):S2-S26. doi: 10.1038/ajg.2014.187.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/25091148/pubmed\" target=\"_blank\" id=\"25091148\">25091148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garey KW, Salazar M, Shah D, et al, &ldquo;Rifamycin Antibiotics for Treatment of Clostridium difficile-Associated Diarrhea,&rdquo; <i>Ann Pharmacother</i>, 2008, 42(6):827-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/18430792/pubmed\" target=\"_blank\" id=\"18430792\">18430792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson S, Schriever C, Galang M, et al, &ldquo;Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy With Vancomycin and Rifaximin,&rdquo; <i>Clin Infect Dis</i>, 2007, 44(6):846-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/17304459/pubmed\" target=\"_blank\" id=\"17304459\">17304459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maclayton DO and Eaton-Maxwell A, &ldquo;Rifaximin for Treatment of Hepatic Encephalopathy,&rdquo; <i>Ann Pharmacother</i>, 2009, 43(1):77-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/19092143/pubmed\" target=\"_blank\" id=\"19092143\">19092143</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mas A, Rod&eacute;s J, Sunyer L, et al, &ldquo;Comparison of Rifaximin and Lactitol in the Treatment of Acute Hepatic Encephalopathy: Results of a Randomized, Double-Blind, Double-Dummy, Controlled Clinical Trial,&rdquo; <i>J Hepatol</i>, 2003, 38(1):51-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/12480560/pubmed\" target=\"_blank\" id=\"12480560\">12480560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menees S, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2012;107(1):28-35. doi: 10.1038/ajg.2011.355<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/22045120/pubmed\" target=\"_blank\" id=\"22045120\">22045120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phongsamran PV, Kim JW, Cupo Abbott J, et al, &ldquo;Pharmacotherapy for Hepatic Encephalopathy,&rdquo; <i>Drugs</i>, 2010, 70(9):1131-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/20518580/pubmed\" target=\"_blank\" id=\"20518580\">20518580</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. <i>Dig Dis Sci</i>. 2011;56(7):2067-2072. doi: 10.1007/s10620-011-1728-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/21559740/pubmed\" target=\"_blank\" id=\"21559740\">21559740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. <i>Aliment Pharmacol Ther</i>. 2014;39(10):1161-1168. doi: 10.1111/apt.12735.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/24697851/pubmed\" target=\"_blank\" id=\"24697851\">24697851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. <i>Hepatology</i>. 2014;60(2):715-735.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/25042402/pubmed\" target=\"_blank\" id=\"25042402\">25042402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xifaxan (rifaximin) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifaximin-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaxine (rifaximin) [product monograph]. Dundas, Ontario, Canada: Salix Pharmaceuticals Inc; August 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10202 Version 141.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F218514\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F48898244\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F218531\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F218516\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F218524\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F218517\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F10167004\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F10167005\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F218495\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F218483\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F48902902\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F218498\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F218497\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725118\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F803022\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F218487\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F218501\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F218485\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F218525\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F218489\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F218503\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F218504\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F218493\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F218484\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F218500\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F218502\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539924\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10202|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rifaximin-patient-drug-information\" class=\"drug drug_patient\">Rifaximin: Patient drug information</a></li><li><a href=\"topic.htm?path=rifaximin-pediatric-drug-information\" class=\"drug drug_pediatric\">Rifaximin: Pediatric drug information</a></li></ul></div></div>","javascript":null}